

Dabigatran (PRADAXA) Anticoagulation or Thromboprophylaxis [4162]

Use caution in patients with acute renal failure.

Consults

Medications

Select condition for which therapy is being initiated (Single Response) (Selection Required)

Non-valvular atrial fibrillation (to prevent stroke and systemic embolism)

Pharmacy consult to monitor dabigatran (PRADAXA) therapy STAT, Until discontinued, Starting S
Indications: Atrial Fibrillation

dabigatran (PRADAXA) (Single Response)

Use reduced dosing in patients with CrCl of 15-30 mL/min OR patients with a CrCl of 30-50 mL/min with concomitant dronedarone or ketoconazole use.

Avoid use in patients with CrCl LESS THAN 15 mL/min, on dialysis, OR with CrCl LESS than 30 mL/min with concomitant use of any P-gp inhibitors (eg amiodarone, clarithromycin, dronedarone, ketoconazole, verapamil, and others) or P-gp inducers (eg. rifampin).

Normal dosing 150 mg, oral, 2 times daily
Indications: Atrial Fibrillation

Reduced dosing 75 mg, oral, 2 times daily
Indications: Atrial Fibrillation

Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Pharmacy consult to monitor dabigatran (PRADAXA) therapy STAT, Until discontinued, Starting S
Indications: Deep vein thrombosis / Pulmonary embolism

dabigatran (PRADAXA)

For initiation after 5 days of initial therapy with a parenteral anticoagulant (ie: heparin infusion, enoxaparin).

Avoid use in patients with CrCl LESS than 30 mL/min or on dialysis.

Avoid use in patients with CrCl LESS than 50 mL/min on any P-gp inhibitors (eg amiodarone, clarithromycin, dronedarone, ketoconazole, verapamil, and others) or P-gp inducers (eg. rifampin).

dabigatran etexilate (PRADAXA) capsule 150 mg, oral, 2 times daily
Indications: Deep vein thrombosis / Pulmonary embolism

Other indication

Pharmacy consult to monitor dabigatran (PRADAXA) therapy STAT, Until discontinued, Starting S
Indications: Other: Specify
Specify Other Indication:

dabigatran (PRADAXA)

dabigatran etexilate (PRADAXA) capsule oral, 2 times daily
Indications: Other
Specify Other Indication:
Indications: Other: Specify

Labs

Baseline Labs

Per HM policy, baseline labs are required prior to initiation of therapy if not already available.

<input checked="" type="checkbox"/> CBC with platelet and differential	Once For 1 Occurrences
<input checked="" type="checkbox"/> Prothrombin time with INR	Once For 1 Occurrences
<input checked="" type="checkbox"/> Partial thromboplastin time, activated	Once For 1 Occurrences
<input checked="" type="checkbox"/> Basic metabolic panel	Once For 1 Occurrences

Follow-up Labs

<input type="checkbox"/> CBC with platelet and differential	AM draw repeats For 3 Occurrences
<input type="checkbox"/> Creatinine level	AM draw repeats For 3 Occurrences
<input type="checkbox"/> CBC with platelet and differential	User Schedule, Starting S+1 For 3 Occurrences
<input type="checkbox"/> Creatinine level	User Schedule, Starting S+1 For 3 Occurrences